Literature DB >> 11139133

The human CYP3A subfamily: practical considerations.

S A Wrighton1, E G Schuetz, K E Thummel, D D Shen, K R Korzekwa, P B Watkins.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11139133     DOI： 10.1081/dmr-100102338

Source DB:  PubMed          Journal:  Drug Metab Rev        ISSN： 0360-2532            Impact factor:   4.518


× No keyword cloud information.
  47 in total

Review 1.  A ligand-based approach to understanding selectivity of nuclear hormone receptors PXR, CAR, FXR, LXRalpha, and LXRbeta.

Authors:  Sean Ekins; Leonid Mirny; Erin G Schuetz
Journal:  Pharm Res       Date:  2002-12       Impact factor: 4.200

2.  Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel.

Authors:  Jung-Won Suh; Bon-Kwon Koo; Shu-Ying Zhang; Kyung-Woo Park; Joo-Youn Cho; In-Jin Jang; Dong-Soon Lee; Dae-Won Sohn; Myoung-Mook Lee; Hyo-Soo Kim
Journal:  CMAJ       Date:  2006-06-06       Impact factor: 8.262

3.  A support vector machine approach to classify human cytochrome P450 3A4 inhibitors.

Authors:  Jan M Kriegl; Thomas Arnhold; Bernd Beck; Thomas Fox
Journal:  J Comput Aided Mol Des       Date:  2005-03       Impact factor: 3.686

Review 4.  Evolution and function of the NR1I nuclear hormone receptor subfamily (VDR, PXR, and CAR) with respect to metabolism of xenobiotics and endogenous compounds.

Authors:  E J Reschly; Matthew D Krasowski
Journal:  Curr Drug Metab       Date:  2006-05       Impact factor: 3.731

5.  Empirical regioselectivity models for human cytochromes P450 3A4, 2D6, and 2C9.

Authors:  Robert P Sheridan; Kenneth R Korzekwa; Rhonda A Torres; Matthew J Walker
Journal:  J Med Chem       Date:  2007-06-19       Impact factor: 7.446

6.  Metabolic enzyme considerations in cancer therapy.

Authors:  Amit K Jain; Sweta Jain; A C Rana
Journal:  Malays J Med Sci       Date:  2007-01

Review 7.  Correlating structure and function of drug-metabolizing enzymes: progress and ongoing challenges.

Authors:  Eric F Johnson; J Patrick Connick; James R Reed; Wayne L Backes; Manoj C Desai; Lianhong Xu; D Fernando Estrada; Jennifer S Laurence; Emily E Scott
Journal:  Drug Metab Dispos       Date:  2013-10-15       Impact factor: 3.922

8.  Hydroxylation and N-dechloroethylation of Ifosfamide and deuterated Ifosfamide by the human cytochrome p450s and their commonly occurring polymorphisms.

Authors:  Diane M Calinski; Haoming Zhang; Susan Ludeman; M Eileen Dolan; Paul F Hollenberg
Journal:  Drug Metab Dispos       Date:  2015-05-01       Impact factor: 3.922

9.  Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines.

Authors:  Edith J Mensah-Osman; Dafydd G Thomas; Michelle M Tabb; Jose M Larios; Dennis P Hughes; Thomas J Giordano; Michelle L Lizyness; James M Rae; Bruce Blumberg; Paul F Hollenberg; Laurence H Baker
Journal:  Cancer       Date:  2007-03-01       Impact factor: 6.860

10.  Effect of borneol on cytochrome P450 3A enzyme and midazolam pharmacokinetics in rats.

Authors:  Rong Zhang; Sui-Qing Mi; Ning-Sheng Wang
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-04-16       Impact factor: 2.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.